| For: | Bessone F, Bjornsson ES. Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach. World J Hepatol 2022; 14(7): 1269-1276 [PMID: 36158917 DOI: 10.4254/wjh.v14.i7.1269] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v14/i7/1269.htm |
| Number | Citing Articles |
| 1 |
Randy Adiwinata, Caroline Tanadi, Fegita Pajala, Kevin Tandarto, Maureen Stella, Jeffry Tenggara, Ralph Gunarsa, Paulus Simadibrata, Lianda Siregar, Saut Nababan, Budiman Sulaiman, Irsan Hasan, Cosmas Lesmana, Aru Sudoyo. Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review. Rambam Maimonides Medical Journal 2026; 17(1): e0005 doi: 10.5041/RMMJ.10571
|
| 2 |
Malek Shatila, Hao Chi Zhang, Anusha Shirwaikar Thomas, Antonio Pizuorno Machado, Sidra Naz, Nitish Mittal, Christine Catinis, Krishnavathana Varatharajalu, Carolina Colli Cruz, Eric Lu, Deanna Wu, Julie R Brahmer, Franck Carbonnel, Stephen B Hanauer, Bret Lashner, Bryan Schneider, John A Thompson, Michel Obeid, David P Farris, Yinghong Wang. Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events. Journal for ImmunoTherapy of Cancer 2024; 12(11): e009742 doi: 10.1136/jitc-2024-009742
|
| 3 |
Einar S. Bjornsson, Daiana Arnedillo, Fernando Bessone. Secondary Sclerosing Cholangitis due to Drugs With a Special Emphasis on Checkpoint Inhibitors. Liver International 2025; 45(4) doi: 10.1111/liv.16163
|
| 4 |
Tomoyuki Otsuka, Yoshiko Hashii, Sei Murayama, Yasunobu Ishizuka, Yoshiki Kojitani, Minako Nishio, Toshihiro Kudo. Checkpoint inhibitor-induced gastritis followed by delayed severe hepatitis in a patient with lung metastases of head and neck squamous cell carcinoma: a case report. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1164236
|
| 5 |
Robert J. Fontana, Einar S. Bjornsson, Rajender Reddy, Raul J. Andrade. The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. Clinical Gastroenterology and Hepatology 2023; 21(8): 2088 doi: 10.1016/j.cgh.2022.12.040
|
| 6 |
Nelia Hernandez, Fernando Bessone, Raul Andrade. Emerging role of immunotherapy for cancer as a major cause of drug-induced liver injury. Annals of Hepatology 2024; 29(5): 101520 doi: 10.1016/j.aohep.2024.101520
|
| 7 |
Fernando Bessone, Einar S. Björnsson. Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors. Medical Clinics of North America 2023; 107(3): 623 doi: 10.1016/j.mcna.2022.12.008
|
| 8 |
Thomas M. Ruli, Ethan D. Pollack, Atul Lodh, Charles D. Evers, Christopher A. Price, Mohamed Shoreibah. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review. Cancers 2024; 16(11): 2042 doi: 10.3390/cancers16112042
|
| 9 |
Klaudia Steplewski, Lucy Walker, Nefeteria Coffee, Maura Fallon, Rie Yonemochi, David Alpers, Don Rockey, James Lewis, Eric Cohen, John Caminis, Judith Hey-Hadavi, Raul Jesus Andrade, Melissa Palmer. IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials. Drug Safety 2025; 48(8): 855 doi: 10.1007/s40264-025-01540-x
|
| 10 |
Gres Karim, Megha Reddy, Navim Mobin, Ilan Weisberg, Amreen Dinani. Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity. Clinical Liver Disease 2024; 23(1) doi: 10.1097/CLD.0000000000000096
|
| 11 |
Angioletta Lasagna, Paolo Pedrazzoli, Raffaele Bruno, Paolo Sacchi. Postvaccination immune-mediated hepatitis: what do we really know?. Immunotherapy 2023; 15(9): 627 doi: 10.2217/imt-2023-0038
|
| 12 |
Cathrin L.C. Gudd, Roosey Sheth, Mark R. Thursz, Evangelos Triantafyllou, Lucia A. Possamai. Immune Checkpoint Inhibitor-Induced Liver Injury. Seminars in Liver Disease 2023; 43(04): 402 doi: 10.1055/s-0043-1776761
|
| 13 |
Donna Zhuang, David Zhang, Stephen Riordan. Hepatobiliary complications of immune checkpoint inhibitors in cancer. Exploration of Targeted Anti-tumor Therapy 2024; 5(4): 955 doi: 10.37349/etat.2024.00257
|
